DOCSLIB.ORG

Lllllllllllllllllllllllllllillllllllllllllllllllllllllllllll

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lllllllllllllllllllllllllllillllllllllllllllllllllllllllllll lllllllllllllllllllllllllllIlllllllllllllllllllllllllllllllllllllllllllllll 0500517515411 United States Patent [191 [11] Patent Number: 5,175,154 Schwartz et a1. [45] Date of Patent: Dec. 29, 1992 [54] 5 a-PREGNAN-ZO-ONES AND Malloux. et al., in Bulletin de la Societe Chemique de S-PREGNEN-ZO-ONES AND RELATED France. 617 (1969). COMPOUNDS Pouzar et a1. Chem. Abstracts 94:103670p ( 1980) “Ste [75] Inventors: Arthur G. Schwartz, Philadelphia; roids. Part CCXXXIV, Absolute Con?guration at C30 Marvin L. Lewbart, Media. both of of the Derivatives of 21-Nor-52-Cho1one-20,~ Pa. 24-Dio1“. Danilewicz et al., CA 62: 91936 1965. [73] Assignee: Research Corporation Technologies, Gravestock et a1. CA 92: 2156245 1980. Inc. Hanson, et al., Perkin Transactions 1, (1977), pp. [21] Appl. No; 126,310 499-501. Chemical Abstracts, 89. 1058656, (1978). [22] Filed: Nov. 25, 1987 Numazawa, et al., Steroids, 32. 519-527 (1978). [51] Int. C1.5 .................... .. A61K 31/58; A61K 31/56 (List continued on next page.) [52] 13.8. Cl. .................................. .. 514/172; 514/182; 514/909 [58] Field of Search ........................... .. 260/397, 397.5; Primary Examiner-Frederick E. Waddell 552/541-544, 546. 551-552. 554-556, 559-560, Assistant Examiner-Raymond J. Henley, Ill 562. 564. 565. 567-568. 582-583. 585, 589, 599, Attorney, Agent, or Firm—Scully, Scott, Murphy & 603-606, 609-616, 623-624, 650-652, 514. 536, Presser 537-539. 548: G23/182, 172 [56] References Cited [57] ABSTRACT US. PATENT DOCUMENTS Compounds of the formulae: 2.833.793 5/1958 Dodson et a1. ................... .. 514/178 2.911.418 11/1959 Johns et al. ....... .. 514/178 3.131.125 4/1964 Wettstein et a1. .. 514/182 3.148.1983.211.723 10/19659/1964 GoldkampKagan ............................ et a1. .. 260/3973 3.318.789 5/1967 3.391.166 7/1968 3.471.480 10/1969 Fritsch et a1. ..... .. 3.471.5263.639.598 10/19692/1972 Klimstra et............ a1. .. 3.836.629 9/1974 Klimstra ............ .. 3.890.3563.914.265 10/19756/1975 GrunwellMiddleton et......... al. .. 3.976.691 8/1976 Middleton et a1. 4.029.777 6/1977 Engelfried et a1. .. 4,628,052 12/1986 Peat et a1. ......................... .. 514/171 FOREIGN PATENT DOCUMENTS 133995 3/1985 European Pat. Off. 210665 2/1987 European Pat. Off. 1239306 4/1964 Fed. Rep. of Germany . 2035738 6/1970 Fed. Rep. of Germany‘. 2705917 2/1977 Fed. Rep. of Germany . 2317934 2/1977 France . 989503 8/1963 United Kingdom . OTHER PUBLICATIONS Remington's Pharmaceutical Sciences (16th edition) 1980; pp. 420-435. Bishop et al., J. Chem. Soc., Chem. Commun. (1983), pp. 123-124. Pouzar et al., Collection Czech. Chem. Commun. (1981) 46, pp. 917-925. Pouzar et al., Collection Czech. Chem. Commun. (1980) 45, pp. 2443-2451. useful as anti-obesity, anti-diabetic, anti-coronary and Gravestock eta1., J. Amer. Chem. Soc., 102:2 (1980) pp. hypolipidemic agents. 800-807, Bull et al., S.-Afr. Tydskr. Chem, (1979) 32(1) pp. 17-22. Danilewicz et al., J. Chem. Soc. 1965 (Feb.) 1306-1319. 98 Claims, No Drawings 5,175,154 Page 2 OTHER PUBLICATIONS Denny, et al., in J. C.S. Perkin I, 486 (1972). Bridgeman. et al., in J. Chem. Soc. C. 250 (1970). Swern, Fels Report, pp. 32-33 (date unknown). Chemical Abstracts 67, 54331k (1967). Abou-Gharbia, et 21]., Journal of Pharmaceutical Sci Catsoulacos, Yet 21., in J. Org. Chem, 32, 3723—3724 ences, 70, 1154 (1981). (1967). Pashko, et al., Carcinogenesis, 2, 717-721 (1981). Sheppard, et al., in Some Chemistry of i3-Iso-Steroids, Pashko, et a1.. Carcingenesis, 5, 463-466 (1984). 2551 (1977). Raineri and Levy, Biochemistry, 9, 2233 (1970). Pelc, et al., in Collection Czechoslov. Chem. Commun. 31, Robinson, st 211.. J. Org. Chem, 28. 975 (1963). 1064 (1966). Neef, et al., J. afOrg. Chem, 43, 4679-4680 (1978). Klimstra, et al., in Journal ofMed. Chem. 9, 924 (1966). Gordon, et al., Cancer Research 46, 3389-3395 (1986). Bishop et 211., CA 99:88445e 1983. Julian, et al., in JACS, 70, 3872-3876 (1948). Pouzar et al., CA 95:1875162 1981. Ross, et al., in J. Chem. Soc, 25 (1945). Pradhan et 211., CA 95:62499q 1981. Crabb, et al., in J.C.S. Perkin 1, 1041 (1981). Bull et al., CA 92:111221s 1980. Chemical Abstracts 92, 215616v (1980). Kocovsky et 211., CA 90:204358r 1979. Bird. et al., in J.C.S. Perkin I, 750 (1980). Allinger, CA 65:5504d 1966. Kirk. et 211., in J. CS. Perkin I, 762 (1976). Scherico, CA 69:97013s 1968. Chemical Abstracts 79, 42723 (1973). Vandcnheuvcl, CA 85:59846t 1975. 5,175,154 1 2 droepiandrosterone: an anti-obesity and anti-carcino 5 ot-PREGNAN-ZO-ONES AND genic agent." Nut. Cancer 3. 46-53 (1981). 5-PREGNEN-20-ONES AND RELATED Ben-David. et al.. “Anti-hypercholesterolemic effect COMPOUNDS of dehydroepiandrosterone in rats.“ Proc. Soc. Expt. Biol. Med, 125, 1136-1140 (1967) have observed that BACKGROUND OF THE INVENTION DHEA treatment has an anti-hypercholesterolemic This invention relates to novel steroids and more effect in mice. while Coleman, et al. (Diabetes 31, 830. particularly to 17-formyl and 17-alkanoyl derivatives of 1982) report that administration of DHEA produces a Sa-androstanes and S-androstenes useful as anti-obesity, marked hypoglycemic effect in C57BL/KsJ-db/db anti-diabetic, anti-coronary and hypolipidemic agents. mice. The latter authors suggest that the therapeutic Dehydroepiandrosterone (DHEA) and DHEA-sul effect of DHEA might result from its metabolism to fate are major adrenal secretory products in humans, estrogens. The plasma concentration of DHEA-sulfate, which It is further known that DHEA and l6c1-bromoepian drosterone are inhibitors of Epstein-Barr virus-induced next to cholesterol, is the most abundant steroid in hu transformation of human lymphocytes and that 16a mans, undergoes the most marked age-related decline of any known steroid. bromoepiandrosterone is a more potent inhibitor of Although DHEA-sulfate is the main precursor of mammalian G6PDl-I than DHEA. See, Schwartz, et a1. placental estrogen and may be converted intoactive Carcinogensis, Vol. 2 No. 7, 683-686 (1981). While DHEA has been found effective in the afore androgens in peripheral tissue, there is no obvious bio 20 described manners, there is however, evidence of an logical role for either DHEA or DHEA-sulfate in the estrogenic effect after prolonged administration. normal individual. Several retrospective and prospec DHEA is not an estrogen per se but is well known to be tive studies suggest that women with sub-normal levels convertible into estrogens. In addition, the therapeutic of these steroids may be predisposed to develop breast dose of DHEA is rather high. It would therefore be cancer. For example, see Brownsey, et al., "Plasma 25 highly desirable to provide steroids. which while hav dehydroepiandrosterone sulfate levels in patients with ing the same afore-described advantage of DHEA are benign and malignant breast disease," Eur. J. Cancer, 8, more potent and do not produce an estrogenic effect. 131-137 (1972): Bulbrook. et al., “Relation between Besides DHEA. other steroids are known in the art. urinary androgen and corticoid excretion and subse Great Britain Patent No. 989.503 to Burn, et a1. dis quent breast cancer," Lancet. 2, 395-398 (1971); Rose, closes 6, 1 6/3 -dimethy1-3 B-hydroxyandrost-S-en et al.. "Plasma dehydroepiandrosterone sulfate, andro 17-ones. These compounds are disclosed to be useful as stenedione and cortisol, and urinary free cortisol excre possessing pituitary inhibiting action. tion in breast cancer, "Eur. J. Cancer, 13, 43-47 (1977); US. Pat. No. 2,833,793 to Dodson, et al. discloses Wang. et al., "Studies of the sulfate esters of dehydro 35 1B,3B-dihydroxy-5-androsten-l7-one as an androgenic epiandorsterone and androsterone in the blood of and anabolic agent. women with breast cancer," Eur, J. Cancer, 10, 477-482 US Pat. No. 2,911,418 to Johns. et a1. discloses 16a (1974); and Zumoff, et al., “Abnormal 24-hr mean chloro-3B-hydroxyandrost-Sen-17-one and 3,8 plasma concentrations of dehydroisoandrosterone and hydroxy-l6a-iodandrost-5-en-17-one as an anti-andro dehydroisoandrosterone sulfate in women with primary gen. operable breast cancer,“ Cancer Research, 41, Goldkamp, et al. in US. Pat. No. 3,148,198 disclose 3360-3363, September, 1981. that 160.,16B-dif1uoro-3B-hydroxyandrost-S-en-17-one It has also been established that DHEA is a potent possess androgenic properties. non-competitive inhibitor of mammalian glucose-6 French Application No. FR-A 2,317,934 discloses the phosphate dehydrogenase (GéPDl-l). For example, see 45 following compounds: Oertel, et al., "The effects of steroids on glucose-6 3,8-hydroxy-16?-methylandrost-5-en-l7-one phosphate dehydrogenase," J. Steroid Biochem, 3, 3B-hydroxy-16?-ethylandrost-5-en-17-one 493-496 (1972) and Marks, et a1, “Inhibition of mamma 3B-hydroxy-lé?-isopropylandrost-S-en-17-one lian glucose-6-phosphate dehydrogenase by steroids,” US. Pat. No. 3,976,691 discloses the following com Proc. Nat‘l Acad. Sci, USA, 46, 477-452 (1960). More pounds: over, Yen, et al., “Prevention of obesity in Al'y/a mice by' dehydroepiandrosterone,” Lipids, 12, 409-413 (1977), reported that long-term administration of 0 (a) DHEA to VY-A‘Wa mice prevented the development of obesity without suppressing appetite. 55 Furthermore, it is also known that the long-term )W treatment of C3I-I mice with DHEA, in addition to reducing weight gain without suppressing appetite, markedly inhibits spontaneous breast cancer develop HO \ ment and may delay the rate of aging. It has been ob o (b) served that DHEA antagonizes the capacity of the 11 tumor promoter, 1Z-O-tetradecanoylphorbol-13-ace tate, to stimulate 3’I-I-thymidine incorporation in mouse epidermis and in a cultured rat kidney epithelial cell line.
Load more

Recommended publications
  • Genome-Wide Identification of Brain Mirnas in Response to High
    Zhao et al. BMC Molecular Biol (2019) 20:3 https://doi.org/10.1186/s12867-019-0120-4 BMC Molecular Biology RESEARCH ARTICLE Open Access Genome‑wide identifcation of brain miRNAs in response to high‑intensity intermittent swimming training in Rattus norvegicus by deep sequencing Yanhong Zhao1*†, Anmin Zhang2,3*†, Yanfang Wang4, Shuping Hu3, Ruiping Zhang2 and Shuaiwei Qian2 Abstract Background: Physical exercise can improve brain function by altering brain gene expression. The expression mecha- nisms underlying the brain’s response to exercise still remain unknown. miRNAs as vital regulators of gene expres- sion may be involved in regulation of brain genes in response to exercise. However, as yet, very little is known about exercise-responsive miRNAs in brain. Results: We constructed two comparative small RNA libraries of rat brain from a high-intensity intermittent swim- ming training (HIST) group and a normal control (NC) group. Using deep sequencing and bioinformatics analysis, we identifed 2109 (1700 from HIST, 1691 from NC) known and 55 (50 from HIST, 28 from NC) novel candidate miRNAs. Among them, 34 miRNAs were identifed as signifcantly diferentially expressed in response to HIST, 16 were up- regulated and 18 were down-regulated. The results showed that all members of mir-200 family were strongly up- regulated, implying mir-200 family may play very important roles in HIST response mechanisms of rat brain. A total of 955 potential target genes of these 34 exercise-responsive miRNAs were identifed from rat genes. Most of them are directly involved in the development and regulatory function of brain or nerve.
    [Show full text]
  • Growth Cone Responses to Growth and Chemotropic Factors
    European Journal of Neuroscience European Journal of Neuroscience, Vol. 28, pp. 268–278, 2008 doi:10.1111/j.1460-9568.2008.06327.x Growth cone responses to growth and chemotropic factors Staci D. Sanford,1 Jesse C. Gatlin,1,* Tomas Ho¨kfelt2 and Karl H. Pfenninger1 1Departments of Pediatrics, and of Cell and Developmental Biology, and Neuroscience Program, University of Colorado School of Medicine, and University of Colorado Cancer Center, Aurora, CO 80045, USA 2Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden Keywords: attractants, axonal pathfinding, growth cone, growth promotion, neuropeptides, repellents Abstract During nervous system development axons reach their target areas under the influence of numerous guidance cues that affect rate and direction of growth. This report addresses the unsettled question of whether and to what extent growth velocity and turning responses (attraction, repulsion) are interdependent. We exposed individual growth cones of fetal rat dorsal root ganglion neurons in culture asymmetrically to gradients of seven different factors and recorded their growth rates and turning angles. Growth cones exhibited divergent patterns of turning and growth responses. For example, hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1) and thrombin all promoted growth, but HGF was a powerful attractant, thrombin a potent repellent and IGF-1 did not elicit turning. Galanin and neuropeptide Y also affected growth and ⁄ or turning differentially. Finally, nerve growth factor in the culture
    [Show full text]
  • Permeability Due to Drug Binding Kinetics and Reactivation Among
    Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability This information is current as of September 26, 2021. Mohammad Fallahi-Sichani, JoAnne L. Flynn, Jennifer J. Linderman and Denise E. Kirschner J Immunol 2012; 188:3169-3178; Prepublished online 29 February 2012; doi: 10.4049/jimmunol.1103298 Downloaded from http://www.jimmunol.org/content/188/7/3169 Supplementary http://www.jimmunol.org/content/suppl/2012/02/29/jimmunol.110329 http://www.jimmunol.org/ Material 8.DC1 References This article cites 59 articles, 21 of which you can access for free at: http://www.jimmunol.org/content/188/7/3169.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 26, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Differential Risk of Tuberculosis Reactivation among Anti-TNF Therapies Is Due to Drug Binding Kinetics and Permeability Mohammad Fallahi-Sichani,*,1 JoAnne L.
    [Show full text]
  • REVIEW Estrogens and Atherosclerosis
    R13 REVIEW Estrogens and atherosclerosis: insights from animal models and cell systems Jerzy-Roch Nofer1,2 1Center for Laboratory Medicine, University Hospital Mu¨nster, Albert Schweizer Campus 1, Geba¨ude A1, 48129 Mu¨nster, Germany 2Department of Medicine, Endocrinology, Metabolism and Geriatrics, University of Modena and Reggio Emilia, Modena, Italy (Correspondence should be addressed to J-R Nofer at Center for Laboratory Medicine, University Hospital Mu¨nster; Email: [email protected]) Abstract Estrogens not only play a pivotal role in sexual development but are also involved in several physiological processes in various tissues including vasculature. While several epidemiological studies documented an inverse relationship between plasma estrogen levels and the incidence of cardiovascular disease and related it to the inhibition of atherosclerosis, an interventional trial showed an increase in cardiovascular events among postmenopausal women on estrogen treatment. The development of atherosclerotic lesions involves complex interplay between various pro- or anti-atherogenic processes that can be effectively studied only in vivo in appropriate animal models. With the advent of genetic engineering, transgenic mouse models of atherosclerosis have supplemented classical dietary cholesterol- induced disease models such as the cholesterol-fed rabbit. In the last two decades, these models were widely applied along with in vitro cell systems to specifically investigate the influence of estrogens on the development of early and advanced atherosclerotic lesions. The present review summarizes the results of these studies and assesses their contribution toward better understanding of molecular mechanisms underlying anti- and/or pro-atherogenic effects of estrogens in humans. Journal of Molecular Endocrinology (2012) 48, R13–R29 Introduction circumstances, these hormones promote the develop- ment of atherosclerosis.
    [Show full text]
  • Network-Based Characterization of Drug-Protein Interaction Signatures
    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
    [Show full text]
  • Guidelines for Pharmacists Performing Clinical Interventions
    Guidelines for pharmacists performing clinical interventions PSA Committed to better health © Pharmaceutical Society of Australia Ltd. 2018 This publication contains material that has been provided by the Pharmaceutical Society of Australia (PSA), and may contain material provided by the Commonwealth and third parties. Copyright in material provided by the Commonwealth or third parties belong to them. PSA owns the copyright in the publication as a whole and all material in the publication that has been developed by PSA. In relation to PSA owned material, no part may be reproduced by any process except in accordance with the provisions of the Copyright Act 1968 (Cwth), or the written permission of PSA. Requests and inquiries regarding permission to use PSA material should be addressed to: Pharmaceutical Society of Australia, PO Box 42, Deakin West ACT 2600. If you would like to use material that has been provided by the Commonwealth or third parties, contact them directly. Disclaimer Neither the PSA, nor any person associated with the preparation of this document, accepts liability for any loss which a user of this document may suffer as a result of reliance on the document and, in particular, for: • use of the Guidelines for a purpose for which they were not intended • any errors or omissions in the Guidelines • any inaccuracy in the information or data on which the Guidelines are based or which is contained in them • any interpretations or opinions stated in, or which may be inferred from, the Guidelines. Notification of any inaccuracy or ambiguity found in this document should be made without delay in order that the issue may be investigated and appropriate action taken.
    [Show full text]
  • Plasma Steroid-Binding Proteins: Primary Gatekeepers of Steroid Hormone Action
    230 1 G L HAMMOND Steroid bioavailability 230:1 R13–R25 Review Open Access Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action Correspondence Geoffrey L Hammond should be addressed Departments of Cellular & Physiological Sciences and Obstetrics & Gynaecology, to G L Hammond University of British Columbia, Vancouver, British Columbia, Canada Email [email protected] Abstract Biologically active steroids are transported in the blood by albumin, sex hormone- Key Words binding globulin (SHBG), and corticosteroid-binding globulin (CBG). These plasma f albumin proteins also regulate the non-protein-bound or ‘free’ fractions of circulating f sex hormone-binding globulin steroid hormones that are considered to be biologically active; as such, they can be f corticosteroid-binding viewed as the ‘primary gatekeepers of steroid action’. Albumin binds steroids with globulin limited specificity and low affinity, but its high concentration in blood buffers major f testosterone fluctuations in steroid concentrations and their free fractions. By contrast, SHBG and f estradiol Endocrinology CBG play much more dynamic roles in controlling steroid access to target tissues and f glucocorticoids of cells. They bind steroids with high (~nM) affinity and specificity, with SHBG binding f progesterone androgens and estrogens and CBG binding glucocorticoids and progesterone. Both are f serine protease inhibitor Journal glycoproteins that are structurally unrelated, and they function in different ways that extend beyond their transportation or buffering functions in the blood. Plasma SHBG and CBG production by the liver varies during development and different physiological or pathophysiological conditions, and abnormalities in the plasma levels of SHBG and CBG or their abilities to bind steroids are associated with a variety of pathologies.
    [Show full text]
  • Theranostics R13 Preserves Motor Performance in SOD1G93A Mice By
    Theranostics 2021, Vol. 11, Issue 15 7294 Ivyspring International Publisher Theranostics 2021; 11(15): 7294-7307. doi: 10.7150/thno.56070 Research Paper R13 preserves motor performance in SOD1G93A mice by improving mitochondrial function Xiao Li1,2#, Chongyang Chen2#, Xu Zhan2#, Binyao Li3, Zaijun Zhang4, Shupeng Li5, Yongmei Xie6, Xiangrong Song7, Yuanyuan Shen8, Jianjun Liu1, Ping Liu2, Gong-Ping Liu2,9, Xifei Yang1 1. Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Medical Key Subject of Modern Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, 518055, China. 2. Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Tianjin Institute of Pharmaceutical Research New Drug Assessment Co. Ltd, Tianjin 300301, China. 4. Institute of New Drug Research and Guangzhou, Key Laboratory of Innovative Chemical Drug Research in Cardio-Cerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou 510632, China. 5. School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China. 6. State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Sichuan University, Chengdu, China. 7. Department of Critical Care Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. 8. National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Health Science Center, Shenzhen University, Shenzhen, 518060, China. 9. Co-innovation Center of Neuroregeneration, Nantong University, Nantong, JS, China. #These authors contributed equally to this work.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen Et Al
    US 2008O161324A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0161324 A1 Johansen et al. (43) Pub. Date: Jul. 3, 2008 (54) COMPOSITIONS AND METHODS FOR Publication Classification TREATMENT OF VRAL DISEASES (51) Int. Cl. (76) Inventors: Lisa M. Johansen, Belmont, MA A63/495 (2006.01) (US); Christopher M. Owens, A63L/35 (2006.01) Cambridge, MA (US); Christina CI2O I/68 (2006.01) Mawhinney, Jamaica Plain, MA A63L/404 (2006.01) (US); Todd W. Chappell, Boston, A63L/35 (2006.01) MA (US); Alexander T. Brown, A63/4965 (2006.01) Watertown, MA (US); Michael G. A6II 3L/21 (2006.01) Frank, Boston, MA (US); Ralf A6IP3L/20 (2006.01) Altmeyer, Singapore (SG) (52) U.S. Cl. ........ 514/255.03: 514/647; 435/6: 514/415; Correspondence Address: 514/460, 514/275: 514/529 CLARK & ELBNG LLP 101 FEDERAL STREET BOSTON, MA 02110 (57) ABSTRACT (21) Appl. No.: 11/900,893 The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain (22) Filed: Sep. 13, 2007 embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particu Related U.S. Application Data lar embodiments, the viral disease is viral hepatitis (e.g., (60) Provisional application No. 60/844,463, filed on Sep. hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E). 14, 2006, provisional application No. 60/874.061, Also featured are screening methods for identification of filed on Dec. 11, 2006. novel compounds that may be used to treat a viral disease.
    [Show full text]
  • NIH Pediatrics Research Report FY2019
    DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Report to Congress: Pediatric Research in Fiscal Year 2019 September 2020 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Report to Congress: Pediatric Research in Fiscal Year 2019 TABLE OF CONTENTS Table of Contents ....................................................................................................................... i PEDIATRIC RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH................................... 1 NEW IN FY 2019 ...................................................................................................................... 1 THE PEDIATRIC RESEARCH INITIATIVE................................................................................ 2 SELECTED SCIENTIFIC RESEARCH ADVANCES IN PEDIATRICS ........................................... 3 Pregnancy and Newborn Health 3 Child Development 6 Social and Environmental Influences 7 Nutrition and Obesity 10 Diabetes 12 Childhood Diseases 13 Immunity and Allergies 17 Rare Pediatric Diseases 19 Pediatric Cancer 19 Bone and Muscle Health 23 Oral Health, Speech, Hearing, and Vision 25 Intellectual and Developmental Disabilities, Neurological Disorders, and Mental Health 26 Childhood Injuries, Maltreatment, and Violence 31 Substance Use and Misuse 32 Pediatric Critical Care and Emergency Care 35 Clinical Care, Outreach, and Services 37 Pediatric Pharmacology 38 Technology and Tools 39 Global Pediatric Health 40 SELECTED NEW AND EXPANDED RESEARCH EFFORTS FOR FY 2019 IN PEDIATRICS
    [Show full text]
  • Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Compr Physiol Manuscript Author . Author Manuscript Author manuscript; available in PMC 2020 July 07. Published in final edited form as: Compr Physiol. ; 10(1): 125–170. doi:10.1002/cphy.c190011. Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure James Hester1, Corey Ventetuolo2,3, Tim Lahm*,1,4,5 1Department of Medicine, Division of Pulmonary, Allergy, Critical Care, Occupational and Sleep Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA 2Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA 3Department of Health Services, Policy and Practice, Brown University School of Public Health, Providence, Rhode Island, USA 4Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA 5Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, USA Abstract Pulmonary hypertension (PH) encompasses a syndrome of diseases that are characterized by elevated pulmonary artery pressure and pulmonary vascular remodeling and that frequently lead to right ventricular (RV) failure and death. Several types of PH exhibit sexually dimorphic features in disease penetrance, presentation, and progression. Most sexually dimorphic features in PH have been described in pulmonary arterial hypertension (PAH), a devastating and progressive pulmonary vasculopathy with a 3-year survival rate <60%. While patient registries show that women are more susceptible to development of PAH, female PAH patients display better RV function and increased survival compared to their male counterparts, a phenomenon referred to as the “estrogen paradox” or “estrogen puzzle” of PAH. Recent advances in the field have demonstrated that multiple sex hormones, receptors, and metabolites play a role in the estrogen puzzle and that the effects of hormone signaling may be time and compartment specific.
    [Show full text]
  • Tandem Mass Spectrometry Method for the Analysis of Androgens, Estrogens, Glucocorticoids and Progestagens in Human Serum
    medRxiv preprint doi: https://doi.org/10.1101/2021.04.12.21255305; this version posted April 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Development and validation of a productive liquid chromatography- tandem mass spectrometry method for the analysis of androgens, estrogens, glucocorticoids and progestagens in human serum Michele Iannone1§, Anna Pia Dima2,3§, Francesca Sciarra2, Francesco Botrè1,2,#* and Andrea M. Isidori2 1. Laboratorio Antidoping FMSI, Largo Onesti 1, 00197 Rome, Italy 2. Department of Experimental Medicine, “Sapienza” University of Rome, Viale Regina Elena, 291, 00161 Roma, Italy 3. Analytical Development & Validation, Merck Italia, Via Luigi Einaudi, 11, 00012 Guidonia RM # Present address: REDs – Research and Expertise in antiDoping sciences, ISSUL – Institute of sport sciences, University of Lausanne, Synathlon, Quartier Centre, 1015 Lausanne Switzerland § Equally contributed * Corresponding author NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.04.12.21255305; this version posted April 19, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved.
    [Show full text]